Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression in newly diagnosed diabetes subclinical vascular lesions

AIM:To investigate the effect of Danzhijiangtang capsule(DJC) on monocyte chemoattractant protein-1(MCP-1) mRNA expression in newly diagnosed type 2 diabetes mellitus(T2DM) subclinical vascular lesions.METHODS:Sixty-two patients with newly diagnosed T2DM subclinical vascular lesions were randomly divided into a control group and treatment group of 31 cases each.Oral antidiabetic therapy with routine western medicine was conducted in both groups,and the treatment group was additionally treated with DJCs.The treatment course for both groups was 12 wk.Before and after treatment,the total efficiency and traditional Chinese medicine(TCM) syndrome score were calculated.The fasting plasma glucose(FPG),2-h plasma glucose(2hPG),fasting insulin(FINS),insulin resistance index(IRI),hemoglobin(Hb)A1c,blood lipids,and hemorheology indices were determined.In addition,the levels of vascular endothelial growth factors including thrombomodulin(TM),von Willebrand factor(vWF),P-selectin and MCP-1 mRNA were determined.RESULTS:After 12 wk of treatment,the TCM syndrome score was significantly decreased compared to before treatment in both groups.After treatment,FPG,2hPG,HbA1c,FINS,IRI,total cholesterol,triglycerides,low-density lipoprotein,high-density lipoprotein,whole blood low shear specific viscosity,plasma specific viscosity,TM,vWF,P-selectin and MCP-1 mRNA were significantly improved compared to before treatment in both groups.After treatment,the total efficiency and TCM syndrome score in the treatment group were better than in the control group.FINS,IRI,whole blood high shear specific viscosity,plasma specific viscosity,TM,vWF,P-selectin and MCP-1 mRNA level in the treatment group were significantly reduced after treatment compared with control group.CONCLUSION:DJCs are efficacious in supplementing qi,nourishing yin and invigorating blood circulation,and upregulate MCP-1 mRNA expression in patients with T2DM subclinical vascular lesions.

Effects of Simvastatin on NF-κB-DNA Binding Activity and Monocyte Chemoattractant Protein-1 Expression in a Rabbit Model of Atherosclerosis

To observe the effects of simvastatin on nuclear factor kappaB （NF-kB）-DNA binding activity and on the expression of monocyte chemoattractant protein-1 （MCP-1） in atherosclerotic plaque in rabbits and to explore the anti-atherosclerotic properties beyond its lipid-lowering effects. Thirty-six New Zealand male rabbits were randomly divided into low-cholesterol group （LC）, high- cholesterol group （HC）, high-cholesterol＋ simvastatin group （HC＋S） and then were fed for 12 weeks. At the end of the experiment, standard enzymatic assays, electrophoretic mobility shift as- say （EMSA）, immunohistochemical staining, and morphometry were performed to observe serum lipids, NF-kB-DNA binding activity, MCP-1 protein expression, intirna thickness and plaque area of aorta respectively in all three groups. Our results showed that the serum lipids, NF-kB-DNA binding activity, expression of MCP-1 protein, intima thickness, and plaque area of aorta in the LC and HC＋S groups were significantly lower than those in the HC group （P〈0.05）. There was no significant difference in the serum lipids between the LC and HC＋S groups （P〉0.05）, but the NF-kB-DNA binding activity, the expression of MCP-1 protein and the intirna thickness and plaque area of aorta in the HC＋S group were significantly decreased as compared to the LC group （P〈0. 05）. This study demonstrated that simvastatin could decrease atherosclerosis by inhibiting the NF-kB-DNA binding activity and by reducing the expression of MCP-1 protein.

Expression of Monocyte Chemoattractant Protein-1 in Monocytes and Effects of Native and Oxidized Very Low Density Lipoproteins

Monocyte chemoattractant protein-1(MCP-1), a potent chemoattractant, is thought to play an important role in migration of monocytes into atherosclerotic lesions. The present study was designed to investigate the capacity of human peripheral blood monocytes to express MCP-1 and effects of native very low density lipoprotein (VLDL) and oxidized VLDL(OX-VLDL) on the expression. The total RNA was extracted from cultured monocytes, which were exposed to VLDL and OX-VLDL, and the media conditioned by monocytes were collected. MCP-1 mRNA expression was examined by Northern blot analysis. MCP-1 protein in conditioned media was determined by using sandwich ELISA. The results showed that monocytes can express MCP-1 after a 24 h incubation at 37℃，and the expression was markedly increased by a exposure to OX-VLDL, whereas the expression was slightly increased when exposed to VLDL. It suggests that the capacity of monocytes to produce MCP-1 that recruits and activates circulating monocytes may be of considerable importance in atherogenesis, and oxidation of VLDL enhances its potential to promote atherogenesis.

Correlation of serum cyclophilin A and monocyte chemoattractant protein-1 levels with carotid atherosclerosis in patients with acute cerebral infarction

Objective:To study the correlation of serum cyclophilin A (CyPA) and monocyte chemoattractant protein-1 (MCP-1) levels with carotid atherosclerosis in patients with acute cerebral infarction.Methods: 106 patients with acute cerebral infarction who were hospitalized in our hospital between July 2011 and August 2015 were selected as observation group, and 50 cases of healthy persons who received physical examination in our hospital during the same period were selected as normal control group. The serum CyPA and MCP-1 contnets in two groups were determined. According to the median of CyPA and MCP-1 contents in observation group, they were divided into high CyPA group and low CyPA group as well as high MCP-1 group and low MCP-1 group, 53 cases in each group. Contents of lipid metabolism indexes and carotid atherosclerosis illness-related indicators were compared between acute cerebral infarction patients with different CyPA and MCP-1 contents.Results:Serum CyPA and MCP-1 contents in observation group were significantly higher than those in control group. Serum TC, LP(a) and LDL-C contents in high CyPA group and high MCP-1 group were higher than those in low CyPA group and low MCP-1 group while HDL-C contents were lower than those in low CyPA group and low MCP-1 group. Serum CysC, Hcy and UA contents in high CyPA group and high MCP-1 group were higher than those in low CyPA group and low MCP-1 group.Conclusion: Serum CyPA and MCP-1 contents in patients with acute cerebral infarction are higher than those in normal population, and the contents of CyPA and MCP-1 are positively correlated with the degree of carotid atherosclerosis.

The enhancement of astrocytic-derived monocyte chemoattractant protein-1 induced by the interaction of opiate and HIV tat in HIV-associated dementia

HIV-associated dementia(HAD)is a public health problem and is particularly prevalent in drug abusers.The neuropathogenesis of human immunodeficiency virus(HIV)infection involves a complex cascade of inflammatory events,including monocyte/macrophage infiltration in the brain,glial immune activation and release of neurotoxic substances.In these events,astrocytic-derived monocyte chemoattractant protein-1(MCP-1)plays an important role,whose release is elevated by HIV transactivator of transcription(HIV tat)and could be further elevated by opiates.This review will also consider some critical factors and events in MCP-1 enhancement induced by the interactions of opiate and HIV tat,including the mediating role of mu opioid receptor(MOR)and CCR2 as well as the possible signal transduction pathways within the cells.Finally,it will make some future perspectives on the exact pathways,new receptors and target cells,and the vulnerability to neurodegeneration with HIV and opiates.

Variation of Serum Monocyte Chemoattractant Protein-1 in Patients with Diabetes and Metabolic Syndrome

This study investigated the variation of serum monocyte chemoattractant protein-1（MCP-1） in patients with both diabetes mellitus（DM） and metabolic syndrome（MS）.Based on the International Diabetes Federation（IDF） diagnostic criteria,93 patients enrolled in this study were divided into four groups：normal control（NC）,simple DM,simple MS,and DM plus MS（DM-MS） groups.The main measures included height,weight,waist circumference（WC）,hip circumference,blood pressure,fasting blood glucose,insulin resistance index（HOMA-IR）,serum triglyceride（TG）,HDL-ch,LDL-ch,and MCP-1.The results showed that the serum levels of MCP-1 in the DM-MS group were significantly increased as compared with those in the DM and MS groups（P0.05）,and the increase in the MCP-1 level in the DM group was much higher than in the MS group（P0.05）.The DM-MS group had the highest HOMA-IR levels,followed by MS,DM and NC groups（P0.05）.Correlation tests showed that the association of MCP-1 with age,HDL-ch,or LDL-ch was insignificant,whereas that of MCP-1 with body mass index（BMI）,waist hip rate（WHR）,WC,systolic blood pressure（SBP）,diastolic blood pressure（DBP）,TG,and HOMA-IR was significantly positive.It was concluded that circulating MCP-1 was substantially increased in patients with both DM and MS as compared with that in the patients with DM or MS alone,and the central obese state may contribute to a more vicious proinflammatory condition and insulin resistance in patients with diabetes.

Monocyte chemoattractant protein-1 plays a key role in type 1 diabetes

Type 1 diabetes is an autoimmune dise as e resulting from the selective destruction of β cells in the pa ncreatic islets. In both human and rodent models of type 1 diabetes, the clinica l disease is preceded by a progressive mononuclear cell invasion of the pancreat ic islets (insulitis). In the early stage of insulitis,the major components are monocyte/macrophages, and the recruitment of mononuclear cells is a critical st ep in the pathogenesis of the type 1 diabetes. Studies have revealed that Monocy te chemoattractant protein-1(MCP-1) specifically recruits monocytes/ macrophag es into pancreas and plays an important role in the development of insulitis and diabetes.

Effect of Llinagliptin on tumor necrosis factor receptor and monocyte chemoattractant protein-1 in patients with diabetic nephropathy

Objective:To explore the effect of Linagliptin on tumor necrosis factor receptor and monocyte chemoattractant protein-1 in patients with diabetic nephropathy.Methods: A total of 98 patients with diabetic nephropathy admitted to the Hospital from January 2017 to September 2018 were enrolled. The patients were divided into two groups according to the random double-blind method, with 49 cases in each group. The control group was treated with Metformin, whereas the experimental group was treated with Linagliptin plus Metformin. After 3 months of continuous treatment, the renal function [urinary albumin excretion rate, 24 h urine protein quantitation and serum creatinine], glycolipids metabolic levels [glycated hemoglobin, fasting blood glucose, total cholesterol and triglycerides], monocyte chemoattractant protein-1, tumor necrosis factor receptor, high-sensitivity C-reactive protein, and adverse reactions were compared between the two groups.Results:After 3 months of treatment, the levels of UAER, 24 h Upor and Scr in the experimental group were shown to be lower than those in the control group, and the difference was statistically significant. After 3 months of treatment, the levels of HbA1c, FPG, TC and TG in the experimental group were shown to be lower than the control group, and the difference was statistically significant. After 3 months of treatment, the levels of MCP-1, sTNFR1 and hs-CRP in the experimental group were lower than those in the control group, and the difference was statistically significant. There was no significant difference in incidence of adverse reactions between the two groups.Conclusion: For patients with diabetic nephropathy, Linagliptin is with higher safety, which can help improve their glycolipids metabolic levels and renal function, reduce the inflammatory response and the levels of MCP-1 and sTNFR1, and yet incur fewer adverse reactions.

Role of monocytes and macrophages in experimental and human acute liver failure

Acute liver failure (ALF) is a devastating clinical syndrome characterised by progressive encephalopathy, coagulopathy, and circulatory dysfunction, which commonly leads to multiorgan failure and death. Central to the pathogenesis of ALF is activation of the immune system with mobilisation of cellular effectors and massive production of cytokines. As key components of the innate immune system, monocytes and macrophages are postulated to play a central role in the initiation, progression and resolution of ALF. ALF in humans follows a rapidly progressive clinical course that poses inherent difficulties in delineating the role of these pivotal immune cells. Therefore, a number of experimental models have been used to study the pathogenesis of ALF. Here we consider the evidence from experimental and human studies of ALF on the role of monocytes and macrophages in acute hepatic injury and the ensuing extrahepatic manifestations, including functional monocyte deactivation and multiple organ failure.

Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells

Background Advanced oxidation protein products （AOPPs） are new uremic toxins reported by Witko-Sarsat in 1996, which are associated with the pathogenesis of atherosclerosis. However, the mechanisms by which AOPPs enhance atherosclerosis have not been fully understood. Monocyte chemoattractant protein-1 （MCP-1） is a chemokine which stimulates migration of monocytes and plays a critical role in the development of atherosclerosis. In this study, we investigated the effect of AOPPs on MCP-1 expression in cultured vascular smooth muscle cells （VSMCs）.

Urotensin Ⅱ promotes monocyte chemoattractant protein-1 expression in aortic adventitial fibroblasts of rat

Background Urotensin Ⅱ （Ull）,a potent vasoconstrictive peptide,is able to stimulate phenotypic differentiation of adventitial fibroblasts.This study aimed to determine the effect of UII on monocyte chemoattractant protein-1 （MCP1） expression in rat aortic adventitial fibroblasts,so as to explore possible mechanisms in the development of vascular inflammation.Methods Growth-arrested adventitial fibroblasts were incubated in serum-free medium with UII （1010-10-7 mol/L） and inhibitors of signal transduction pathways for 1 to 24 hours.MCP-1 mRNA and protein expression and secretion were determined by RT-PCR,Western blotting analysis and enzyme-linked immunosorbent assay （ELISA）,respectively.Results UII dose-and time-dependently promoted MCP-1 mRNA and protein expression and secretion in cells,with maximal effect at 10-8 mol/L at 3 hours for mRNA expression,24 hours for protein expression in the cells,and 12 hours for protein secretion from the cells.Furthermore,the UII effects were significantly inhibited by treatment with its receptor antagonist SB710411,Rho kinase inhibitor Y27632,protein kinase C （PKC） inhibitor H7,mitogen-activated protein kinase inhibitor PD98059,calcineurin inhibitor cyclosporine A,and the Ca2＋channel blocker nicardipine.Conclusion UII may stimulate MCP-1 expression in rat aortic adventitial fibroblasts through its receptor and Rho kinase,PKC,mitogen-activated protein kinase,calcineurin and Ca2＋ channel signal transduction,thus contributing to adventitial inflammation.

Effects of Wenxiao Decoction(稳消方) on the Expression of Interleukin-6,Intercellular Adhesion Molecular-1and Monocyte Chemoattractant Protein-1 in Experimental Atherosclerotic Rabbits

Objective： To observe the effects of different doses of Wenxiao Decoction （稳消方） on the expression of interleukin-6 （IL-6）, intercellular adhesion molecule-1 （ICAM-1）, and monocyte chemoattractant protein-1 （MCP-1） in experimental atherosclerotic rabbits and to explore the mechanism by which it alleviates atherosclerosis. Methods： Sixty New Zealand rabbits were randomly divided into six groups： a blank group, a model group, a Simvastatin group, and high-, medium-, and low-dosage Wenxiao Decoction groups. Except for those in the blank group, all rabbits were fed with a high-cholesterol diet. Carotid atherosclerosis was established by balloon-induced carotid artery endothelium injury in conjunction with the high-cholesterol diet. After 8 weeks, all animals were euthanized to evaluate levels of IL-6 and ICAM-1 expressions （by enzyme linked immunosorbent assay） and of MCP-1 （by immunohistochemistry staining）. Results： The expressions of IL-6, ICAM-1, and MCP-1 were significantly increased in all groups except the blank group （P〈0.05）. However, the rabbits in the Wenxiao Decoction groups and the Simvastatin group showed significantly lower levels of IL-6, ICAM-1, and MCP-1 expression than those in the model group （P〈0.05）. The expressions of IL-6, ICAM-1, and MCP-1 in the high- dosage Wenxiao Decoction group and the Simvastatin group were lower than those in the low-dosage Wenxiao Decoction group （P〈0.05）. The expression of MCP-1 in medium-dosage Wenxiao Decoction group was lower than that in the low-dosage group （P〈0.05）. Conclusions： High, medium, and low doses of Wenxiao Decoction can inhibit the expressions of IL-6, ICAM-1, and MCP-1, which may prevent and stabilize atherosclerotic plaques. There may be a direct relationship between dosage and therapeutic efficacy of Wenxiao Decoction.

Expression of monocyte chemoattractant protein-1 in the pancreas of mice

Background Type 1 diabetes has been recognized as an organ specific autoimmune disease owing to the immune destruction of pancreatic islet β cells in genetically susceptible individuals. In both human and rodent models of type 1 diabetes, such as nonobese diabetic （NOD） mice, biobreeding rats, the disease has a distinct stage characterized by immune cells infiltrating in the pancreas （insulitis）. The major populations of infiltrating cells are macrophages and T lymphocytes. Therefore, immune cell infiltration of pancreatic islets may be a crucial step in the pathogenesis of type 1 diabetes. Monocyte chemoattractant protein-1 can specifically attract monocytes in vivo. Interferon induced protein-10 has chemoattractant effects on the activated lymphocytes. In this study, we analysed the expression of monocyte chemoattractant protein-1 in the pancreas of mice and interferon inducible protein-10 mRNA in the pancreas of NOD mice, and discussed their possible role in the pathogenesis of type 1 diabetes. Methods The immunohistochemical method and immunoelectronmicroscopy were used to evaluate the expression of monocyte chemoattractant protein-1 in the pancreas of NOD mice and BALB/c mice. RT-PCR was used to evaluate the expression of monocyte chemoattractant protein-1 and interferon inducible protein mRNA in NOD mice. Results Monocyte chemoattractant protein-1 was positive in the pancreas of NOD mice, whereas negative in the pancreas of BALB/C mice. RT-PCR showed that monocyte chemoattractant protein-1 and interferon inducible protein-10 mRNA could be found in the pancreas of NOD mice. Immunoelectronmicroscopy demonstrated that monocyte chemoattractant protein-1 was produced by β cells and stored in the cytoplasm of the cells. Conclusions Pancreatic islet β cells produce monocyte chemoattractantprotein-1 in NOD mice. Monocyte chemoattractant protein-1 may play an important part in the pathogenesis of type 1 diabetes by attracting monocytes/macrophages to infiltrate pancreatic islets.

达格列净治疗早期糖尿病肾病的疗效及对血清MCP-1、IL-6水平的影响

目的探讨达格列净治疗早期糖尿病肾病的疗效及对血清单核细胞趋化因子-1(MCP-1)、白细胞介素-6(IL-6)水平的影响。方法选择昆明医科大学第二附属医院于2019年1月至2020年1月期间收治的78例早期糖尿病肾病患者为研究对象,随机分为观察组与对照组,每组39例,2组均接受厄贝沙坦等常规治疗,对照组患者予二甲双胍降糖,观察组患者则应用达格列净降糖,疗程为12周。比较2组患者治疗前后血肌酐、空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、尿白蛋白排泄率(UAER)以及血清MCP-1、IL-6水平的变化。结果治疗后,2组FBG、2 h PG及HbA1c均明显降低,且观察组均明显低于对照组,差异有统计学意义(P<0.05);治疗后,2组UAER较治疗前明显降低,且观察组低于对照组,差异有统计学意义(P<0.05);2组患者治疗前后血肌酐水平均无明显变化(P>0.05);治疗后,2组患者血清MCP-1、IL-6水平均较治疗前明显下降,且观察组明显低于对照组,差异有统计学意义(P<0.05)。Peason相关性分析表明,早期糖尿病肾病患者UAER与血清MCP-1、IL-6水平均呈正相关性(P<0.05)。结论达格列净应用于早期糖尿病肾病的治疗,不仅可以有效控制患者的血糖,还可以降低血清MCP-1、IL-6水平,减少尿蛋白的漏出,进而保护患者的肾功能。

单核细胞趋化蛋白-1和血管内皮生长因子mRNA在急性甲醇中毒大鼠脑组织的表达

目的观察大鼠急性甲醇中毒后脑组织趋化因子单核细胞趋化蛋白1(MCP-1)及血管内皮生长因子(VEGF)mRNA水平的表达变化.方法健康成年SD大鼠75只,应用通有混合气体(N2O/O2)的密闭有机玻璃箱并灌胃相应剂量甲醇溶液复制急性高剂量甲醇中毒大鼠和急性低剂量甲醇中毒大鼠(n=5).分不同时段(2h,12 h,24 h,3 d,1周)取大鼠右心房静脉血,采用气相色谱法检测大鼠血液的甲醇浓度,取大鼠脑组织进行总RNA提取,经逆转录得cDNA,用SYBRGreen荧光实时定量PCR技术动态定量监测脑组织中MCP-1和VEGF mRNA在急性甲醇中毒后不同时间点表达的变化.结果 (1)甲醇浓度检测结果:低剂量组在2 h、12 h的血液甲醇浓度较生理盐水组显著升高(P<0.05),高剂量组在2 h、12 h、24 h的血液甲醇浓度较低剂量组和生理盐水组显著升高(P<0.05),各组在3 d和1周均未测出甲醇;(2)MCP-1 mRNA表达变化:在甲醇中毒后2 h明显升高,24 h达到高峰,各个时间点与对照组比较均有显著性差异(P<0.05),在2 h,3 d和1周高剂量组高于低剂量组;(3)VEGF mRNA表达变化:在甲醇中毒后2 h明显升高,24 h达到高峰,各个时间点与对照组比较均有显著性差异(P<0.05),在2 h和12 h高剂量组高于低剂量组.结论急性甲醇中毒后,MGP-1和VEGF mRNA的表达显著升高,程度与甲醇中毒剂量有关,可能在脑损伤形成和发展过程中起着重要作用.

血清胱抑素C、单核细胞趋化蛋白1在早期糖尿病肾病的检测

目的:探讨血清胱抑素C(Cystatin C,Cys-C)和单核细胞趋化蛋白1(Monocyte chemoattractant protein-1,MCP-1)在早期糖尿病肾病的临床价值。方法:横断面研究选取90例2型糖尿病患者没有明显的临床糖尿病肾病(diabetic kidney disease,DKD),按照简化MDRD公式计算的肾小球滤过率(e GFR)和尿蛋白肌酐比值(u Acr)分为四组:A组(e GFR>90 ml·min-1·1. 73 m-2,u Acr <30 mg/g Cr,23例),B组(e GFR> 90 ml·min-1·1. 73 m-2,u Acr 30～300 mg/g Cr,21例),C组(e GFR 60～89 ml·min-1·1. 73 m-2,u Acr <30 mg/g Cr,26例),D组(e GFR 60～89 ml·min-1·1. 73 m-2,u Acr 30～300 mg/g Cr,20例),同时设立25例健康对照组(E组)。分别收集各组患者各项临床特征并检测血、尿肌酐、MDRD公式计算e GFR、u ACR、血Cys-C、MCP-1水平。结果:(1) e GFR及u Acr均正常的糖尿病患者(A组)血Cys-C水平较健康对照组无显著性升高(P> 0. 05),而e GFR正常伴微量蛋白尿(B组)及e GFR降低不伴(C组)或伴微量蛋白尿(D组)的早期糖尿病肾病患者血Cys-C水平较对照组均显著性升高(P <0. 05);血Cys-C与e GFR呈显著负相关(r=-0. 486,P <0. 01);血Cys-C与血肌酐、u Acr水平呈显著正相关(r=0. 442,r=0. 319,P <0. 01);(2)糖尿病各组(A、B、C、D组)血MCP-1水平较对照组均显著性升高(P <0. 05),但各组间差异均无统计学意义(P> 0. 05),血MCP-1与e GFR、血肌酐、u Acr无显著相关(r=-0. 191,r=0. 143,r=0. 176,P> 0. 05)。结论:血Cys-C在2型糖尿病患者肾损伤早期阶段即表达升高,较血肌酐更灵敏的检测出糖尿病患者早期肾损伤的发生,而血MCP-1不能早期检测糖尿病肾病。

IgA肾病单核细胞趋化蛋白-1含量的动态变化及临床意义

目的:探讨IgA肾病患者血液、尿液中单核细胞趋化蛋白-1(MCP-1)含量的动态变化及其临床意义。方法:将46例患者按24 h尿蛋白定量分为两组,即大量蛋白尿组和小量蛋白尿组;选取20例正常人为对照组;采用酶联免疫吸附法(ELISA)检测对照组血液、尿液MCP-1;实验组治疗前后两次尿液和治疗前血液MCP-1的含量进行对比。结果:IgA肾病患者尿液中MCP-1的含量明显增高,大量蛋白尿组高于小量蛋白尿组和正常对照组,且小量蛋白尿组亦高于对照组。治疗有效组患者40例,治疗前期尿液中MCP-1的含量高于治疗后期,经分析差异有统计学意义(P<0.01)。IgA肾病患者尿液中MCP-1的含量与24 h尿蛋白定量呈正相关,而患者血液中MCP-1的含量与正常对照组比较差异无统计学意义(P>0.05)。结论:IgA肾病的发病与MCP-1有关。监测IgA肾病患者尿液MCP-1含量具有安全、标本易获得的特点,尿液MCP-1含量可作为临床上评价IgA肾病患者病情严重程度和预后的无创性生物指标,从而减少了重复肾穿刺活检的次数。

糖尿病肾病肾功能不全患者血清单核细胞趋化蛋白-1水平变化

目的探讨不同程度的糖尿病肾病(DN)患者血清单核细胞趋化蛋白-1(MCP-1)的水平及其意义。方法76例2型糖尿病患者分别按尿蛋白定量(UMA)及血清肌酐(Cr)水平分为3组:正常蛋白尿正常肾功能组(A组)UMA≤30mg/24h,Cr≤97μmol/L(女),106μmol/L(男)、显性蛋白尿正常肾功能组(B组)UMA≥300mg/24h,Cr≤97μmol/L(女),106μmol/L(男)和显性蛋白尿合并肾功能不全组(C组)UMA≥300mg/24h,Cr>97μmol/L(女),106μmol/L(男)。选择同期在我院门诊行健康体检的26名健康人作为正常对照组。用酶联免疫吸附法(ELISA法)检测血清MCP-1,并检测糖化血红蛋白(GHbA1c)、血清尿素氮(BUN)、Cr以及尿UMA水平。结果A组患者血清MCP-1水平为(131.1±48.2)ng/L,B组为(265.3±115.4)ng/L,C组为(467.2±101.2)ng/L,正常对照组为(59.3±24.3)ng/L,4组患者血清MCP-1水平比较差异有统计学意义(F=114.01,P<0.05)。多元逐步回归分析显示,对糖尿病显性蛋白尿合并肾功能不全患者影响作用由大到小依次为:尿UMA、GHbA1c和Cr,回归方程复相关系数r=0.517。结论2型糖尿病患者血清MCP-1水平较正常人高,且随着蛋白尿增加和肾功能不全,这种变化更加明显,这种变化可能是高血糖、内皮细胞损伤和毒素刺激共同作用的结果。

血清及尿液单核细胞趋化蛋白1检测在过敏性紫癜肾炎患儿诊断中的价值比较

目的比较血清及尿液单核细胞趋化蛋白1(MCP-1)检测在过敏性紫癜肾炎(HSPN)患儿诊断中的临床价值。方法选取淮安市肿瘤医院2008年2月至2012年10月住院治疗的78例过敏性紫癜肾炎患儿,根据尿白蛋白排泄率(UAER)分为正常白蛋白尿组(A组,27例),微量白蛋白尿组(B组,25例),大量白蛋白尿组(C组,26例),根据疾病病情分为缓解期(n=36例),急性期(n=42例),比较各组血清及尿液MCP-1表达水平及其与尿蛋白排泄率(UAER)的相关性。结果随UAER增加各组尿液MCP-1表达水平呈明显递增趋势(P<0.05),而各组血清MCP-1表达水平比较,差异无统计学意义(P>0.05);急性期尿液MCP-1表达水平显著高于缓解期(P<0.05);缓解期及急性期HSPN患儿血清MCP-1表达水平比较,差异无统计学意义(P>0.05);HSPN患儿尿液MCP-1表达水平与UAER呈正相关(r=0.782,P<0.05),HSPN患儿血清MCP-1表达水平与UAER无相关(r=0.327,P>0.05)。结论尿液MCP-1表达水平与HSPN患儿肾脏组织病变程度和尿蛋白有着密切相关性,对HSPN患儿疾病预后情况判断和临床治疗方案指导有着十分重要的意义。

Effect of pharmacological intervention on MIP-1α,MIP-1β and MCP-1 expression in patients with psoriasis vulgaris

Objective:To detect the expression level of macrophage inflammatory protein-1(MIP-1)α,MIP-1βand monocyte chemoattractant protein-1(MCP-1)in with psoriasis vulgaris and explore the role in the pathogenesis of psoriasis vulgaris.Methods:The level of MIP-1α,MIP-1βand MCP-1 in peripheral blood from 50 patients with psoriasis vulgaris and 50 normal controls were measured by enzyme linked immunosorbent assay.The correlation with psoriasis area and severity index(PASI)was analyzed.The level of MIP-1α,MIP-1βand MCP-1 was compared between psoriasis vulgaris patients at active stage and resting stage.And the change in MIP-1α,MIP-1βand MCP-1 before and after therapy was also observed.Results:The content of MIP-1α,MIP-1βand MCP-1 in patients with psoriasis vulgaris was(1342.78±210.30),(175.28±28.18)and(266.86±32.75)ng/L,respectively,significantly higher than those in control group(P<0.05).The expression level of MIP-1α,MIP-1βand MCP-1 in peripheral blood of patients with psoriasis vulgaris was positively correlated wilh PASI(P<0.01).After acitretin therapy,expression level of MIP-1α,MIP-1βand MCP-1 in peripheral blood of patients with psoriasis vulgaris was significantly decreased.Conclusions:Chemokine factor MIP-1α,MIP-1βand MCP-1 may be involved in the pathogenesis of psoriasis vulgaris.